It is, of course, important that Apple achieve the greatest accuracy, sensitivity, repeatability, etc., for their health features.
However, we should bear in mind that even dedicated pathology labs end up producing results that do not match other labs. In the area with which I am most familiar, the thyroid, reference intervals vary hugely.
For example, Free T4 at one lab could have a reference interval of 12 to 22, and at another 7 to 13. That is, hardly any overlap. And a single blood sample tested at both could be near the top of one, but near the bottom of the other. Indeed, it is unlikely that the sample would achieve 17 on the first, and 10 on the second (mid-reference interval for both). Nor the same numeric result on both.
That is without even considering the numerous factors that can and do interfere with blood tests.
One response to a paper:
Global FT4 immunoassay standardization. Response to: Kratzsch J et al. Global FT4 immunoassay standardization: an expert opinion review
https://www.degruyter.com/document/doi/10.1515/cclm-2021-0036/html
I suspect Apple is unlikely to end up doing worse than some established purveyors of analysers.
However, we should bear in mind that even dedicated pathology labs end up producing results that do not match other labs. In the area with which I am most familiar, the thyroid, reference intervals vary hugely.
For example, Free T4 at one lab could have a reference interval of 12 to 22, and at another 7 to 13. That is, hardly any overlap. And a single blood sample tested at both could be near the top of one, but near the bottom of the other. Indeed, it is unlikely that the sample would achieve 17 on the first, and 10 on the second (mid-reference interval for both). Nor the same numeric result on both.
That is without even considering the numerous factors that can and do interfere with blood tests.
One response to a paper:
Global FT4 immunoassay standardization. Response to: Kratzsch J et al. Global FT4 immunoassay standardization: an expert opinion review
https://www.degruyter.com/document/doi/10.1515/cclm-2021-0036/html
I suspect Apple is unlikely to end up doing worse than some established purveyors of analysers.